Security record · archived quarter
AURA
Aura Biosciences, Inc. · Healthcare · Biotechnology
1Tracked holders
0Δ holders
19.13KShares held
$124,441Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 19.13K | $124,441 | n/a | n/a |
| Q2 2026 | 63 | +4 | 26.02M | $184.73M | +7 | −3 |
| Q1 2026 | 61 | +1 | 20.24M | $135.34M | +4 | −3 |
| Q4 2025 | 60 | +2 | 20.07M | $109.37M | +2 | n/a |
| Q3 2025 | 14 | -1 | 14.65M | $90.53M | n/a | −1 |
| Q2 2025 | 12 | +2 | 13.23M | $82.82M | +2 | n/a |
| Q1 2025 | 7 | -1 | 7.63M | $44.69M | n/a | −1 |
| Q4 2024 | 8 | -1 | 7.50M | $61.68M | n/a | −1 |
| Q3 2024 | 8 | 0 | 6.61M | $58.90M | +1 | −1 |
| Q2 2024 | 8 | n/a | 9.02M | $68.17M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 19.13K | +6.6% | $124,441 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 125 holders, 50.86M shares, $337.45M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Oct 01
SC 13G: ForGrowth III PA B.V.
Aug 14
SC 13G/A: Frazier Life Sciences Public Fund, L.P.
Aug 14
SC 13G: Long Focus Capital Management, LLC
Aug 12
SC 13G/A: Adage Capital Management, L.P.
Jul 27
SC 13G/A: BlackRock, Inc.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API